DJIA 16,058.35 -469.68 -2.84%
NASDAQ 4,636.11 -140.40 -2.94%
S&P 500 1,913.85 -58.33 -2.96%
market minute promo


1.17 0.04 (3.54%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $1.17 3.54%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.11
Previous Close $1.13
Daily Range $1.10 - $1.20
52-Week Range $0.94 - $4.82
Market Cap $121.7M
P/E Ratio -1.11
Dividend (Yield) $0.00 (0.0%)
Volume 2,594,829
Average Daily Volume 1,787,356
Current FY EPS -$0.59




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

The 3 Most Disappointing Drug Launches of All Time

Treatments with huge promise don't always pan out the way you'd expect.

Why VIVUS (VVUS) Could Shock the Market Soon

Orexigen: Contrave Wins Another Sales Week - Don't Bank On Impressive Numbers

Vivus Hovers Near 52-Week Lows - Qsymia Sales Not Helping

This Is a Concern That Amgen Investors Shouldn't Take Lightly

Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.

Orexigen- Contrave Sales Win The Week But Still Flatter Than Needed

Arena - Belviq Sales Dip Again. We Have Seen The Peak In 2015

Vivus (VVUS) Flagged As Strong On High Volume

Stocks Trading Near Their 52-Week Lows: 4 Hot Picks

VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%

See More VVUS News...

VVUS's Top Competitors

VVUS $1.17 (3.54%)
Current stock: VVUS
JNJ $92.09 (-2.01%)
Current stock: JNJ
NVS $94.68 (-2.61%)
Current stock: NVS
RHHBY $33.37 (-2.30%)
Current stock: RHHBY